These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19562682)

  • 1. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.
    Fuchs H; Binder R; Greischel A
    Biopharm Drug Dispos; 2009 Jul; 30(5):229-40. PubMed ID: 19562682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
    Greischel A; Binder R; Baierl J
    Drug Metab Dispos; 2010 Sep; 38(9):1443-8. PubMed ID: 20538719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
    Retlich S; Withopf B; Greischel A; Staab A; Jaehde U; Fuchs H
    Biopharm Drug Dispos; 2009 Nov; 30(8):422-36. PubMed ID: 19771584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.
    Fuchs H; Tillement JP; Urien S; Greischel A; Roth W
    J Pharm Pharmacol; 2009 Jan; 61(1):55-62. PubMed ID: 19126297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.
    Retlich S; Duval V; Graefe-Mody U; Jaehde U; Staab A
    J Clin Pharmacol; 2010 Aug; 50(8):873-85. PubMed ID: 20160157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers.
    Hüttner S; Graefe-Mody EU; Withopf B; Ring A; Dugi KA
    J Clin Pharmacol; 2008 Oct; 48(10):1171-8. PubMed ID: 18812608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
    Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
    J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
    Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
    Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
    Med Lett Drugs Ther; 2011 Jun; 53(1367):49-50. PubMed ID: 21701440
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical pharmacokinetics and pharmacodynamics of linagliptin.
    Graefe-Mody U; Retlich S; Friedrich C
    Clin Pharmacokinet; 2012 Jul; 51(7):411-27. PubMed ID: 22568694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
    Fuchs H; Runge F; Held HD
    Eur J Pharm Sci; 2012 Apr; 45(5):533-8. PubMed ID: 22198311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.
    Wright S; Singh RP; Retlich S; Graefe-Mody U; Derendorf H
    Int J Clin Pharmacol Ther; 2012 May; 50(5):323-30. PubMed ID: 22541836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
    Neumiller JJ
    Ann Pharmacother; 2012 Mar; 46(3):358-67. PubMed ID: 22318932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human.
    Wu N; An G
    AAPS J; 2020 Sep; 22(6):125. PubMed ID: 32996028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.